Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SphK1 siRNA
- Development stage
- Preclinical
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intravenous, Intranasal, Intratumoral, Intraperitoneal
01
Overview
SphK1 siRNA is a research-stage small interfering RNA (siRNA) designed to silence the expression of the SPHK1 gene, which encodes sphingosine kinase 1. Sphingosine kinase 1 is a key lipid kinase enzyme in the sphingosine-1-phosphate (S1P) signaling pathway, often overexpressed in various cancers where it promotes tumor progression, metastasis, and chemotherapy resistance. By knocking down SphK1 expression, this RNA interference (RNAi) approach is widely studied in preclinical and academic research across multiple oncology indications, including triple-negative breast cancer, nasopharyngeal carcinoma, neuroblastoma, ovarian carcinoma, and glioma. It is primarily available as a catalog research reagent from laboratory suppliers rather than a clinical-stage therapeutic asset.
- Other names
- small interfering RNA targeting sphingosine kinase 1sphingosine kinase 1 siRNASPHK1 siRNASPHK-1 siRNASPHK 1 siRNA
02
Targets
SPHK1 (Sphingosine kinase 1)
Beyond the preview
Go deeper on SphK1 siRNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SphK1 siRNA.